Literature DB >> 11302563

Serotonin, norepinephrine and dopamine involvement in the antidepressant action of hypericum perforatum.

G Calapai1, A Crupi, F Firenzuoli, G Inferrera, F Squadrito, A Parisi, G De Sarro, A Caputi.   

Abstract

Hypericum perforatum is considered an effective alternative to the synthetic antidepressants in the treatment of mild-to-moderate depression. Recently, we showed that the effects on neurotransmitter contents in different brain regions of laboratory animals are more evident after administration of hypericum extracts containing a higher concentration of flavonoids, thus suggesting that these compounds are important in the antidepressant action of hypericum perforatum. We studied the effects of Ph-50, a hypericum extract standardized to flavonoids (50%) and containing 0.3% hypericin and 4.5% hyperforin on brain serotonin content, norepinephrine and dopamine by a high-performance liquid chromatography method in discrete brain areas (cortex, diencephalon and brainstem) in male Sprague-Dawley rats. Moreover, we evaluated the effects of Ph-50 alone or in association with sulpiride (a dopamine receptor antagonist), metergoline (a serotonin receptor antagonist) and 6-hydroxydopamine (6-OH-DA, destroying norepinephrine-containing neurons) using a forced-swimming test in the rat. Hypericum extract (Ph-50; 250-500 mg/kg) with acute oral administration enhanced serotonin, norepinephrine and dopamine content in the brain and reduced the immobility time of rats in the forced-swimming test. Sulpiride, metergoline and 6-OH-DA significantly increased the period of immobility in the forced-swimming test for the rats receiving hypericum extract (Ph-50). The results indicate that the neurotransmitters studied could be involved in the anti-immobility effects of hypericum, and suggest that its antidepressant action is probably mediated by serotonergic, noradrenergic and dopaminergic system activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302563     DOI: 10.1055/s-2001-15180

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  14 in total

1.  Selected physical and chemical properties of commercial Hypericum perforatum extracts relevant for formulated product quality and performance.

Authors:  S H Kopleman; A NguyenPho; W S Zito; F X Muller; L L Augsburger
Journal:  AAPS PharmSci       Date:  2001

2.  Effects of St John's wort (Hypericum perforatum L.) extracts on epileptogenesis.

Authors:  Vesna Ivetic; Svetlana Trivic; Marija Knezevic Pogancev; Mira Popovic; Janka Zlinská
Journal:  Molecules       Date:  2011-09-19       Impact factor: 4.411

3.  The efficacy of Hypericum perforatum (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Sarah Canning; Mitch Waterman; Nic Orsi; Julie Ayres; Nigel Simpson; Louise Dye
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

4.  Hypericum perforatum attenuates nicotine withdrawal signs in mice.

Authors:  Maria A Catania; Fabio Firenzuoli; Anna Crupi; Carmen Mannucci; Achille P Caputi; Gioacchino Calapai
Journal:  Psychopharmacology (Berl)       Date:  2003-04-29       Impact factor: 4.530

Review 5.  St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?

Authors:  Gita Kholghi; Shirin Arjmandi-Rad; Mohammad-Reza Zarrindast; Salar Vaseghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-16       Impact factor: 3.000

6.  Repeated doses of methylone, a new drug of abuse, induce changes in serotonin and dopamine systems in the mouse.

Authors:  Raúl López-Arnau; José Martínez-Clemente; Sonia Abad; David Pubill; Jorge Camarasa; Elena Escubedo
Journal:  Psychopharmacology (Berl)       Date:  2014-04-05       Impact factor: 4.530

Review 7.  Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review.

Authors:  Su Hee Jang; Dong Il Kim; Min-Sun Choi
Journal:  BMC Complement Altern Med       Date:  2014-01-10       Impact factor: 3.659

8.  GRID-independent molecular descriptor analysis and molecular docking studies to mimic the binding hypothesis of γ-aminobutyric acid transporter 1 (GAT1) inhibitors.

Authors:  Sadia Zafar; Ishrat Jabeen
Journal:  PeerJ       Date:  2019-01-31       Impact factor: 2.984

9.  Clinically relevant safety issues associated with St. John's wort product labels.

Authors:  Kevin A Clauson; Marile L Santamarina; Jennifer C Rutledge
Journal:  BMC Complement Altern Med       Date:  2008-07-17       Impact factor: 3.659

10.  Dose and time-dependent selective neurotoxicity induced by mephedrone in mice.

Authors:  José Martínez-Clemente; Raúl López-Arnau; Sonia Abad; David Pubill; Elena Escubedo; Jorge Camarasa
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.